| Title: | Single time point diagnostic breath tests: a review |
| Address: | "Cambridge Isotope Laboratories Inc., Andover, MA 01810, USA. anilm@isotope.com" |
| DOI: | 10.1088/1752-7155/4/1/017002 |
| ISSN/ISBN: | 1752-7163 (Electronic) 1752-7155 (Linking) |
| Abstract: | "The metabolism of ingested xenobiotics is clinically significant to minimize risk and optimize therapeutic benefits. A majority of the drugs approved by the FDA are metabolized by phase I enzymes. Stable isotope-labeled xenobiotics can be used to provide rapid in vivo phenotype assessment of phase I enzymes. In this paper, we describe three simple, noninvasive phenotype breath tests using [13C]-dextromethorphan and [13C]-pantoprazole for assessing polymorphic CYP2D6 and CYP2C19 enzyme activity and [13C]-uracil to assess the enzyme activity of DPD, DPHD and beta-ureidopropionase for identifying pyrimidine metabolic disorder. The results of the [13C]-dextromethorphan, [13C]-pantoprazole and [13C]-uracil breath test studies suggest that they have great potential for evaluating CYP2D6, CYP2C19 and DPD enzyme activities in a relatively short time with a single time point breath collection in a clinic or hospital setting. This would enable physicians to prescribe personalized therapy for each individual by selecting the ideal medication at the right dose for optimal efficacy of xenobiotics metabolized by these enzymes" |
| Keywords: | Aryl Hydrocarbon Hydroxylases/metabolism Breath Tests/*methods Cytochrome P-450 CYP2C19 Cytochrome P-450 CYP2D6/metabolism Cytochrome P-450 Enzyme System/*metabolism Dihydropyrimidine Dehydrogenase Deficiency/diagnosis Humans Volatile Organic Compounds Xe; |
| Notes: | "MedlineModak, Anil S eng Review England 2009/12/18 J Breath Res. 2010 Mar; 4(1):017002. doi: 10.1088/1752-7155/4/1/017002. Epub 2009 Dec 18" |
